Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Ovarian Dysfunction After Gonadotoxic Therapy in Childhood Cancer Survivors: A Cross-Sectional Study From a Resource-Limited Setting.

Created on 22 Sep 2026

Authors

Heena Gajiwala, Gauri Kapoor, Sandeep Jain, Payal Malhotra, Pooja Sharma, Richa Arora, Anurag Sharma

Published in

Journal of pediatric hematology/oncology. Sep 21, 2026. Epub Sep 21, 2026.

Abstract

Ovarian dysfunction is a life-altering late effect in female childhood cancer survivors (CCS), yet early identification of ovarian injury remains challenging. This study aimed to evaluate the burden and determinants of ovarian dysfunction in CCS, with a specific focus on treatment-related amenorrhea (TRA) persisting for ≥4 months. Demographic, clinical, and treatment exposure data were obtained from the hospital medical records. Menstrual and hormonal information was collected using a structured proforma. In this single-center cross-sectional study, 186 female CCS (mean age: 21±5 y) were evaluated after a mean follow-up of 10±5.6 years. Gonadotoxic exposures included chemotherapy (100%) with a mean cumulative cyclophosphamide equivalent dose (CED) of 5.1 g/m2, pelvic or craniospinal radiotherapy (6.45%), and hematopoietic stem cell transplantation (4.8%). Hypergonadotropic TRA was observed in 24% (45/186) of survivors, and 20% (9/45) of them progressed to acute ovarian failure (AOF). On multivariable analysis, independent predictors of TRA included postpubertal status at diagnosis (OR: 20.45; CI: 4-101.5), solid tumor diagnosis (OR: 5.98; CI: 1.7-8), and CED of ≥7.5 g/m2 (OR: 4.56; CI: 1.4-14). Prevalence of AOF aligned with established risk categories. As an easily identifiable clinical feature, TRA may help identify survivors suitable for fertility preservation counselling and surveillance for premature ovarian failure.

PMID:
42766469
Bibliographic data and abstract were imported from PubMed on 22 Sep 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 13
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement